Navigation Links
Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
Date:6/25/2009

WALTHAM, Mass., June 25 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, pharmacomechanical thrombectomy (PMT) procedure adoption will accelerate over the next five years due to growing physician interest in treating deep vein thrombosis (DVT). Although the ATTRACT (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis) trial, which will compare catheter-directed thrombolysis (CDT) to PMT in the treatment of iliofemoral DVT, will not be completed until approximately 2014, early experience with PMT in this indication is promising. MRG's US Markets for Clot Management Devices 2009 report finds that PMT procedure volumes will thus undergo strong growth through 2013.

PMT procedures are still relatively new. Currently, four PMT devices are being used and/or investigated for the treatment of DVT: MEDRAD Interventional/Possis Medical's AngioJet Power Pulse Spray, Bacchus Vascular/Covidien's Trellis-8 Peripheral Infusion System, EKOS Corporation's EKOS EndoWave Peripheral Infusion System and ev3's Helix Clot Buster Thrombectomy Device. In order to address the clinical controversy regarding whether PMT should be routinely used as a first-line treatment for DVT, Possis Medical, Covidien, and EKOS are collaborating on the ATTRACT trial, which is slated to begin recruitment in July 2009.

"Firms are hoping that results of this trial will clarify the association between rapid clot lysis and the prevention of post-thrombotic syndrome in patients with proximal DVT, as well as demonstrate how PMT may have lower bleeding risks compared with traditional CDT alone," says Darren Navarro, Senior Analyst at MRG. "The reduced lytic doses and shorter treatment times in the intensive care unit afforded by PMT make this procedure safer and more user-friendly for the physician, and more convenient for the patient when compared to standard CDT."

MRG's US Markets for Clot Management Devices 2009 report provides important insight into the drug and device treatments of DVT and the complex competitive dynamics in this field. Additionally, the report provides market analyses for devices that treat arteriovenous, peripheral artery, coronary, and neurovascular thrombosis, including five-year forecasts, up-to-date market shares, and in-depth qualitative insights.

About Pharmacomechanical Thrombectomy

PMT is used predominantly for the treatment of iliofemoral DVT, but can also be used to a lesser extent in the treatment of upper limb DVT and peripheral artery occlusion. PMT combines the direct delivery of "clot-busting" thrombolytic drugs with mechanical clot disruption, and is posited to be safer, more effective, and more efficient than CDT alone due to the lower dose of thrombolytics required for clot dissolution.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThromCat(R) XT(TM) Thrombectomy Catheter System Receives CE Mark
2. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
3. Thrombectomy Device Market to Approach $900 Million by 2013, According to Millennium Research Group
4. OMTECs Opening Keynote Emphasizes Increasing Demand for Orthopaedic Procedures
5. Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin
6. Kevin Niksarli, M.D. of Manhattan Lasik Center is to Discuss the iLASIK Procedure on AMWC Subspecialty Day Meeting on 7/1/2009
7. Simulation helps students learn dental implant procedures
8. TUG Procedure by Texas Health Dallas Cardiologist Offers Hope to Millions of Patients
9. Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options
10. Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas
11. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
(Date:10/12/2017)... CHICAGO (PRWEB) , ... October ... ... innovator in life sciences content management, presents its enhanced Pepper Flow promotional ... Oct. 16 -18, 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: